DACT3

DACT3 is a negative regulator of canonical Wnt/β-catenin signaling that restrains proliferation, invasion, and epithelial-to-mesenchymal transition across multiple epithelial and hematologic malignancies and in fibrotic tissue injury (PMID:18538736, PMID:23580654, PMID:35187752). Mechanistically, DACT3 acts at the level of Dishevelled: it physically binds Dishevelled family members (DVL2, DVL1) and lowers their protein levels, blocking Dvl-driven phosphorylation of GSK-3β (S9) and β-catenin (S675), reducing β-catenin nuclear translocation and β-catenin-dependent transcription (PMID:23580654, PMID:35187752, PMID:40838391). Epistasis confirms a DACT3→DVL2→Wnt/β-catenin axis, since restoring DVL2 reverses DACT3-mediated pathway suppression (PMID:35187752). Through this β-catenin control, DACT3 also dampens downstream transcriptional outputs including c-Myb and c-Myc and suppresses β-catenin-dependent Notch1/NICD signaling (PMID:31966514, PMID:35794797, PMID:38230242). DACT3 expression is itself heavily regulated: it is silenced in colorectal cancer by bivalent histone modifications and derepressed by combined inhibition of histone methylation and deacetylation, induced by HDAC inhibitors in hematologic malignancies, suppressed by miR-638, and upregulated by butyrate from gut microbiota to mediate anti-inflammatory effects in intestinal epithelium (PMID:18538736, PMID:28108314, PMID:33054518, PMID:35794797). Loss of Dapper3/Dact3 in mice causes accumulation of Dvl2 and β-catenin and amplified Wnt-driven renal fibrosis, establishing its role as a tumor- and fibrosis-suppressive Wnt antagonist in vivo (PMID:23580654).

1. 2008 High

   Established that DACT3 is a Wnt/β-catenin antagonist whose silencing in colorectal cancer is epigenetic rather than genetic, opening a therapeutic strategy to restore its expression.

   Evidence Epigenetic profiling, pharmacological co-inhibition of histone methylation and deacetylation, reporter and apoptosis assays in colorectal cancer cells

   PMID:18538736

   Open questions at the time

   • Did not define the direct molecular target through which DACT3 antagonizes Dvl
   • Bivalent chromatin regulators acting on the DACT3 locus not enumerated
2. 2013 High

   Identified the direct binding partner and in vivo consequence: DACT3 binds and downregulates Dvl2, and its genetic loss amplifies Wnt-driven fibrosis, moving from correlation to a defined molecular mechanism.

   Evidence Conditional Dapper3 knockout mice with ureteral obstruction, co-IP for Dapper3–Dvl2, Topflash reporter, Western blot, primary cell EMT assay

   PMID:23580654

   Open questions at the time

   • Mechanism of Dvl2 downregulation (degradation pathway) not resolved
   • Whether the same axis operates in cancer vs fibrosis not directly tested here
3. 2017 Medium

   Placed DACT3 within a post-transcriptional regulatory circuit and linked it to autophagy, showing miR-638 directly represses DACT3 to promote malignant phenotypes.

   Evidence Luciferase reporter of miR-638 targeting DACT3 3'UTR, siRNA knockdown phenocopy, in vitro and xenograft assays in esophageal and breast cancer

   PMID:28108314

   Open questions at the time

   • Mechanistic link between DACT3 loss and autophagy not defined
   • Single lab; not independently replicated
4. 2017 Medium

   Extended DACT3 Wnt suppression to NSCLC and connected it to a specific downstream effector, c-Myb.

   Evidence Gain- and loss-of-function in NSCLC lines with Wnt reporter, invasion and proliferation assays

   PMID:31966514

   Open questions at the time

   • Whether c-Myb regulation is direct or via β-catenin not distinguished
   • No binding-partner experiments in this system
5. 2020 Medium

   Revealed an upstream physiological inducer of DACT3 and a non-cancer role, showing butyrate from gut microbiota upregulates Dact3 to mediate anti-inflammatory effects in intestinal epithelium.

   Evidence Transcriptomic screen of HT-29, siRNA knockdown, butyrate treatment, F. prausnitzii in vivo colitis model

   PMID:33054518

   Open questions at the time

   • Signaling steps linking Dact3 to anti-inflammatory output not mapped
   • Whether Wnt antagonism mediates the anti-inflammatory effect not established
6. 2022 Medium

   Provided epistatic proof of the DACT3→DVL2→Wnt axis in AML by showing DVL2 re-expression reverses DACT3 suppression, and reinforced HDAC-inhibitor derepression as a therapeutic lever.

   Evidence DACT3/DVL2 overexpression epistasis, Wnt reporter, Western blot, AML xenograft (35187752); HDAC inhibitor CKD-581 induction of DACT3 with β-catenin/c-Myc readouts in MM and T cell lymphoma (35794797)

   PMID:35187752 PMID:35794797

   Open questions at the time

   • Mechanism of DVL2 protein downregulation still not biochemically resolved
   • Single-lab studies per malignancy
7. 2023 Low

   Linked DACT3 to Notch cross-talk, showing it suppresses Notch1/NICD signaling in a β-catenin-dependent manner in glioma.

   Evidence DACT3 overexpression in glioma cells, Western blot for β-catenin and NICD, fractionation/IF, functional assays

   PMID:38230242

   Open questions at the time

   • No direct binding or rescue experiments; mechanistic depth limited
   • β-catenin-to-Notch1 connection inferred, not directly demonstrated
8. 2025 Medium

   Resolved the biochemical mechanism of Dvl inhibition by showing DACT3 directly binds DVL1 and blocks DVL1-induced GSK-3β (S9) and β-catenin (S675) phosphorylation, also implicating DACT3 in cisplatin resistance.

   Evidence Co-IP for DACT3–DVL1, IF for β-catenin localization, phospho-Western blots, reporter assay, transfection/knockdown, cisplatin resistance assay in NSCLC

   PMID:40838391

   Open questions at the time

   • Structural basis of DACT3–DVL interaction unknown
   • Whether DVL1 protein is degraded or only functionally inhibited not fully resolved

• The biochemical route by which DACT3 lowers Dishevelled protein levels (degradation machinery, ubiquitin ligases, or interaction interface) remains undefined.
• No structural model of DACT3–DVL complexes
• Degradation pathway for DVL1/DVL2 downregulation not identified
• Mechanism connecting butyrate signaling to DACT3 transcription unmapped